MorphoSys (MOR) Stock Forecast & Price Target

$18.96

0.00 (0.00%)

(As of 09/27/2024 ET)

MorphoSys - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 6 Analyst Ratings

Sell
0

Hold
4

Buy
2

Based on 6 Wall Street analysts who have issued ratings for MorphoSys in the last 12 months, the stock has a consensus rating of "Hold." Out of the 6 analysts, 4 have given a hold rating, and 2 have given a buy rating for MOR.

Consensus Price Target

$11.78
-37.87% Downside

According to the 6 analysts' twelve-month price targets for MorphoSys, the average price target is $11.78. The highest price target for MOR is $18.25, while the lowest price target for MOR is $4.75. The average price target represents a forecasted downside of -37.87% from the current price of $18.96.

Get the Latest News and Ratings for MOR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MorphoSys and its competitors.

MOR Analyst Ratings Over Time

Type	Current Forecast 9/30/23 to 9/29/24	1 Month Ago 8/31/23 to 8/30/24	3 Months Ago 7/2/23 to 7/1/24	1 Year Ago 9/30/22 to 9/30/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$11.78	$11.78	$11.78	$12.81
Forecasted Upside	-37.87% Downside	-37.87% Downside	-35.13% Downside	90.66% Upside
Consensus Rating	Hold	Hold	Hold	Hold

WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)

The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.

Take these 4 steps today to protect your retirement NOW

MOR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MOR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

MorphoSys Stock vs. The Competition

Type	MorphoSys	Medical Companies	S&P 500
Consensus Rating Score	2.33	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	-37.87% Downside	818.50% Upside	6.16% Upside
News Sentiment Rating	Positive News See Recent MOR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/14/2024	Wells Fargo & Company 3 of 5 stars		Reiterated Rating	Overweight ➝ Equal Weight	$17.00 ➝ $18.25	+3.05%
1/19/2024	Morgan Stanley 3 of 5 stars		Reiterated Rating	Overweight ➝ Equal Weight
12/6/2023	Leerink Partnrs 0 of 5 stars	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
12/5/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$10.00 ➝ $8.50	+17.08%
11/22/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$9.25 ➝ $4.75	+10.98%
11/21/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$17.00	+279.46%
7/17/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold
5/31/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
12/22/2022	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sell ➝ Sell	€16.00 ➝ €12.00
11/15/2022	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:20 PM ET.

MOR Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for MorphoSys is $11.78, with a high forecast of $18.25 and a low forecast of $4.75.
: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MOR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
: According to analysts, MorphoSys's stock has a predicted downside of -37.87% based on their 12-month stock forecasts.
: Analysts like MorphoSys less than other "medical" companies. The consensus rating for MorphoSys is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MOR compares to other companies.